OrbiMed Asia

OrbiMed Asia is a prominent healthcare investment firm specializing in global investments across the healthcare industry. With over 25 years of experience, the firm manages approximately $19 billion in assets, investing in both public and private companies worldwide. Their portfolio spans various sectors, including biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.

The firm's investment strategy encompasses a range of stages, from seed-stage startups to large multinational corporations. OrbiMed Asia provides tailored financing solutions, including private equity, public equity, and royalty/credit funds, to support the growth and development of healthcare companies. Their global team of over 130 professionals operates across multiple locations, including New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and London, enabling them to offer extensive resources and expertise to their portfolio companies.

OrbiMed Asia's commitment to responsible investing is evident in their focus on companies dedicated to sustainable growth and long-term shareholder value. They have backed over 110 life sciences startups and have committed over $2 billion to developing-country healthcare, supporting initiatives such as maternal care hospitals in India and dialysis centers in China. Their approach combines substantial financial resources with a global team to partner with exceptional management teams in building world-class healthcare companies.